As viral vaccines are increasingly used to meet global health needs, the pharmaceutical industry is manufacturing larger ...

Low influenza vaccine uptake in India despite high mortality rates; manufacturers scaling up production to meet growing ...

One avenue for new vaccine development is mucosal vaccines. In theory, dosing the vaccine directly into the respiratory tract ...

H5N1 influenza is evolving rapidly, weakening the effectiveness of existing antibodies and increasing its potential threat to ...

Modified live vaccines tend to produce slightly stronger and longer lasting immunity and may provide slightly higher fetal ...

The NIH announced the beginning of a phase 1 first-in-human trial of a vaccine for Lassa fever, a potentially fatal viral hemorrhagic disease for which there is no approved vaccine or treatment.

Most pediatric transplant recipients who received live-attenuated viral vaccines after transplant developed protective ...

NIH has launched a human trial for LASSARAB, a dual-purpose vaccine targeting Lassa fever and rabies. Early animal studies ...

The fears over mRNA-vaccine grant cancellations come after NIH staff members were instructed to compile a list of grants for ...

Scientists at Cornell University have developed a new type of vaccine that may provide stronger and longer-lasting protection ...

Introduction Vaccines are biological preparations that stimulate the immune system to develop protection against specific infectious diseases.

Such vaccines deployed cell culture and used a re-assortment of viral genetic material instead of using attenuated or killed viruses. Genetic engineering made it possible to clone or replicate ...